Singapore’s Theranostics Market, valued at US$ XX billion in 2024 and 2025, is expected to grow steadily at a CAGR of XX% from 2025–2030, reaching US$ XX billion by 2030.
Global theranostics market valued at $1.9B in 2022, reached $2.1B in 2023, and is projected to grow at a robust 15.5% CAGR, hitting $4.3B by 2028.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111696976
Drivers
The Singapore Theranostics Market is significantly driven by the convergence of several key factors, notably the nation’s high-quality healthcare infrastructure and its aggressive push toward personalized oncology. The rising incidence of various cancer types, particularly within the country’s rapidly aging population, creates an urgent demand for highly precise diagnostic and therapeutic solutions that theranostics provides. Singapore’s government, through agencies like the Agency for Science, Technology and Research (A*STAR), actively invests in the biomedical sciences, fostering a rich environment for research and clinical adoption of novel nuclear medicine and molecular imaging technologies. This institutional support helps accelerate the clinical translation of new radiopharmaceuticals and companion diagnostics. Furthermore, the market benefits from a well-established and sophisticated network of specialized medical centers and therapeutic facilities capable of delivering advanced theranostic procedures, such as those utilizing Lutetium-177 or Gallium-68. The increasing availability and acceptance of molecular imaging (PET/CT, SPECT) for pre-therapeutic diagnostics reinforce the demand for integrated theranostic approaches. Lastly, Singapore serves as a critical entry point and regional hub for global pharmaceutical and radiopharmaceutical companies seeking to commercialize their products in Asia, further stimulating market expansion through heightened accessibility to cutting-edge treatments.
Restraints
Despite strong drivers, the Singapore Theranostics Market is constrained by high costs, a complex supply chain, and specialized infrastructure requirements. The development, production, and regulatory approval of radiopharmaceuticals are inherently expensive, translating into high out-of-pocket or insurance costs for patients, which can limit broad accessibility compared to traditional treatments. A critical restraint is the reliance on a complex and logistically challenging supply chain for short-lived radioisotopes. Manufacturing and delivering these time-sensitive materials require highly coordinated, secure, and specialized logistics networks, which increases operational risks and costs. Furthermore, the successful implementation of theranostics demands significant upfront investment in specialized equipment, such as high-energy cyclotrons and advanced SPECT/PET scanners, along with dedicated hot labs and shielded facilities. There is also a notable shortage of highly specialized medical professionals—including nuclear medicine physicians, radiochemists, and medical physicists—trained to administer and interpret these complex therapies and diagnostics. Regulatory pathways, while robust, can be lengthy and challenging for novel theranostic agents that combine both diagnostic and therapeutic components, potentially slowing down market introduction and clinical utilization of new innovations in Singapore.
Opportunities
The Singapore Theranostics Market presents substantial opportunities rooted in technological advancements and strategic expansion. The most promising opportunity lies in expanding the application of theranostics beyond prostate cancer (PSMA-based) into other high-incidence cancers prevalent in Asia, such as hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors, through the development of new targeting agents. The market is poised for growth through strategic collaborations aimed at establishing local or regional radiopharmaceutical manufacturing and compounding capabilities. Such localization would mitigate supply chain vulnerabilities, reduce dependence on international sourcing, and allow for faster customization of doses. Furthermore, leveraging Singapore’s strong digital health and AI ecosystem to integrate theranostic data—combining imaging, genomic, and clinical information—offers a major opportunity to optimize patient selection, monitor treatment response in real-time, and enhance clinical trial efficiency. The focus on developing advanced companion diagnostics that accurately predict patient response to radioligand therapy will also unlock significant commercial value. Finally, Singapore’s position as a regional medical tourism destination offers an opportunity to attract international patients seeking specialized, high-precision theranostic treatments unavailable in their home countries, driving revenue for private healthcare providers.
Challenges
Key challenges for the Singapore Theranostics Market revolve around achieving widespread clinical adoption, standardization, and technology transfer. A significant challenge is the need for standardization in radiopharmaceutical production, quality control, and dosing protocols across different healthcare institutions to ensure reliable and reproducible outcomes. The challenge of translating promising pre-clinical research into commercially viable and scalable clinical products is considerable, requiring bridging the gap between academic innovation and industrial manufacturing capabilities. Despite government support, securing adequate reimbursement and funding mechanisms for these high-cost, cutting-edge treatments remains a hurdle, often limiting access for patients who may benefit. Furthermore, educating the broader clinical community—including general oncologists and primary care physicians—about the specific benefits, risks, and appropriate patient selection criteria for theranostics is essential but challenging. Ensuring regulatory harmony and timely approval for new radiolabeled drugs and devices as they emerge from the pipeline is also crucial. Overcoming these challenges requires coordinated efforts across policymakers, manufacturers, research institutions, and clinicians to streamline processes and build trust in these novel treatment modalities.
Role of AI
Artificial Intelligence (AI) is emerging as a critical enabler and accelerant for the Singapore Theranostics Market, dramatically enhancing efficiency and precision across the value chain. AI algorithms can revolutionize the diagnostic phase by automating and improving the quantitative analysis of molecular images (PET/CT or SPECT). Machine learning models can quickly and accurately delineate tumors, assess tracer uptake, and generate predictive biomarkers from imaging data, leading to more precise diagnosis and treatment planning. In the therapeutic setting, AI is crucial for optimizing personalized radiation dosimetry, allowing physicians to calculate the precise absorbed radiation dose to tumor tissue while minimizing exposure to healthy organs. This capability is vital for maximizing therapeutic efficacy and minimizing side effects. Furthermore, AI can integrate complex patient data—including genetic sequencing, imaging characteristics, and clinical outcomes—to predict which patients will respond best to specific theranostic agents, thereby improving patient stratification and reducing unnecessary treatment costs. Singapore’s national strategy to integrate AI into healthcare provides a supportive framework for developing and deploying these smart theranostic platforms, turning vast amounts of multimodal data into actionable clinical intelligence and accelerating research breakthroughs.
Latest Trends
Several cutting-edge trends are defining the trajectory of Singapore’s Theranostics Market. A dominant trend is the diversification of theranostic targets beyond the established Prostate-Specific Membrane Antigen (PSMA) for prostate cancer. Research and clinical trials are rapidly exploring new radioligands targeting receptors in other prevalent cancers, such as FAP (Fibroblast Activation Protein) for a variety of solid tumors, and CXCR4 for hematological malignancies. Another key trend is the move towards developing Alpha-emitting radioisotopes (e.g., Actinium-225) as therapeutic agents. These offer higher potency and shorter path length compared to traditional Beta-emitters, promising more effective killing of microscopic disease with less damage to surrounding tissue. Furthermore, the integration of companion diagnostics with therapy is becoming increasingly seamless, emphasizing the “one-stop-shop” concept where the diagnostic imaging agent and the therapeutic agent share the same targeting vector. This facilitates true personalized medicine by ensuring that patients only receive treatment if their tumor highly expresses the target molecule. Lastly, there is a growing focus on decentralized production models, including efforts to develop small-scale, automated production units (mini-cyclotrons or generators) within hospital settings. This trend addresses the logistical challenges associated with short radioisotope half-lives, enhancing the efficiency and accessibility of theranostic agents within Singapore’s specialized medical centers.